More than 95% of molecules will never become a saleable drug either because of safety risks or lack of efficacy. The InSilicoTrials platform enables scientists to unleash the power of modeling and simulation in any stage of drug preclinical and clinical trials, to identify as early as possible the best candidates while assessing their efficacy and safety.